Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.40 |
| ▸ | CCR6 | P51684 | 8/20 | 0.36 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22718262 | 0.85 | CCR6 (0.44) | IDH1SIRT2CCR6 | |
| SCHEMBL22843419 | 0.82 | TEAD1 (0.40) | IDH1SIRT2CCR6CCNKCCNA2 | |
| SCHEMBL22843417 | 0.82 | KDM4E (0.37) | CCNA2CDK2RAB9A | |
| SCHEMBL22843399 | 0.81 | MAPT (0.45) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL22843422 | 0.80 | CDK2 (0.36) | CCNA2CDK2TYK2RAB9A | |
| SCHEMBL22843410 | 0.79 | TNNI3K (0.40) | — | |
| SCHEMBL22843415 | 0.75 | CA2 (0.36) | — | |
| SCHEMBL22843472 | 0.72 | KMT2A (0.38) | — | |
| SCHEMBL22843409 | 0.72 | CYP2C9 (0.37) | CDK2 | |
| SCHEMBL29438849 | 0.69 | CCR6 (0.41) | IDH1CCR6TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | IDH1 256/4885SIRT2 1689/4885CCR6 4335/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | IDH1 256/4885SIRT2 1689/4885CCR6 4335/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | IDH1 256/4885SIRT2 1689/4885CCR6 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.